Country/Region: Taiwan
PE Guidelines


PDF in Chinese


PDF in English


HTA guidelines in Taiwan (Chinese)

PE Guidelines Source:

Taiwan Society for Pharmacoeconomics and Outcomes Research
http://www.taspor.org.tw/

Additional Information:
Last Webpage Update: Tuesday, January 23, 2018

PE Guidelines Key Features:

Key Features:  
Title and year of the document
Guidelines of Methodological Standards for Pharmacoeconomic Evaluations (2006) 
Affiliation of authors
Taiwan Society for Pharmacoeconomic and Outcomes Research (TaSPOR) 
Purpose of the document
Provide stakeholders a guide to conduct, evaluate and report a PE study 
Standard reporting format included
Yes 
Disclosure
Yes 
Target audience of funding/ author's interests
Should state clearly 
Perspective
Mainly societal, may separate into payer and others 
Indication
Should be approved by the regulatory body 
Target population
State clearly, may include subgroup analysis 
Subgroup analysis
Yes. Treatment regimen, disease groups, symptom complex, severity of disease, patient characteristics 
Choice of comparator
The one most likely to be replaced, first choice, most effective one, most frequently used. 
Time horizon
Long enough to cover all significant clinical and cost consequences that are directly related to the intervention. 
Assumptions required
Yes 
Preferred analytical technique
The most appropriate method that can reflect the purpose of the study 
Costs to be included
Depends on the perspective of the study. Recommend human capital approach for estimation of indirect cost 
Source of costs
Direct costs from BNHI reimbursement price, state clearly the sources, reflect Taiwan situations 
Modeling
Yes, requires details 
Systematic review of evidences
Recommended 
Preference for effectiveness over efficacy
Yes. Recommend meta-analysis of effectiveness. 
Preferred outcome measure
Life-year gained and QALY 
Preferred method to derive utility
All can be accepted, using general public’s views 
Equity issues stated
Yes 
Discounting costs
Base: 3%; SA: 0 ~ 5% 
Discounting outcomes
Three scenarios: discount cost but not outcome, both discounted, both not discounted 
Sensitivity analysis-parameters and range
All assumptions should be subject to SA. 
Sensitivity analysis-methods
Univariate, Multivariate (best and worst case estimate), 
Presenting results
Both in aggregated and disaggregated form 
Incremental analysis
Yes 
Total costs vs effectiveness (cost/effectiveness ratio)
Yes 
Portability of results (Generalizability)
Yes, Taiwan context, especially the cost issue and epidemiology data 
Financial impact analysis
Yes 
Mandatory or recommended or voluntary
Voluntary 

Acknowledgement: Tony Yen-Huei Tarn contributed to the key feature form.

Country Selection Page | PE Guidelines Index Page